Daniel Alencar Rodrigues

Royal College of Surgeons in Ireland

H指数:14

被引数:1,378

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of a mechanism-based binding mode for a histone deacetylase 6 inhibitor

鉴定组蛋白去乙酰化酶6抑制剂的机制性结合模式

Nature Communications

IF15.7

2026-06-050

OAAI

Design, Synthesis, and Biological Evaluation of Novel Triazine-Based Dual Histone Deacetylase/phosphatidylinositol 3-kinase Inhibitors for Breast Cancer Therapy

基于三嗪的新型组蛋白去乙酰化酶/磷脂酰肌醇3-激酶双抑制剂的设计、合成及生物活性评价：用于乳腺癌治疗

ChemMedChem

IF3.4

2026-04-250

OAAI

Fulfilling Multiple Roles in PROTAC Design: The Emerging Potential of Oligonucleotides

在PROTAC设计中扮演多重角色：寡核苷酸的应用潜力日益显现

European Journal of Medicinal Chemistry

IF5.9

2026-02-130

OAAI

Inhibition of HDAC6 alters fumarate hydratase activity and mitochondrial structure

抑制HDAC6改变延胡索酸水合酶活性和线粒体结构

Nature Communications

IF15.7

2025-07-280

Design, synthesis and pharmacological evaluation of multitarget GPR40 agonists/HDAC6 inhibitors for Alzheimer’s disease

GPR40激动剂/HDAC6抑制剂的阿尔茨海默病多靶点设计、合成与药理学评价

European Journal of Medicinal Chemistry

IF5.9

2025-06-130

PRE

Exploring the Conformational Effects of N- and C-Methylation of N-Acylhydrazones

探索N-酰基肼的N-和C-甲基化构象效应

ACS OMEGA

IF4.3

2025-04-210

Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups

组蛋白去乙酰化酶抑制的药物发现：锌结合基团的过去、现在和未来

PHARMACEUTICALS

IF4.8

2025-04-160

Click-Capable Phenanthriplatin Derivatives as Tools to Study Pt(II)-Induced Nucleolar Stress

ACS CHEMICAL BIOLOGY

IF3.8

2024-03-143

OAAI

First-in-class metallo-PROTAC as an effective degrader of select Pt-binding proteins

CHEMICAL COMMUNICATIONS

IF4.2

2023-01-014

The path to venetoclax resistance is paved with mutations, metabolism, and more

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2022-12-0713

PRE

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer

PHARMACEUTICALS

IF4.8

2021-04-2110

OAAI

Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects

CHEMMEDCHEM

IF3.4

2020-11-0617

PREAI

Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities

MEDICINAL RESEARCH REVIEWS

IF11.6

2020-06-2642

PREAI

Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors

CHEMMEDCHEM

IF3.4

2020-02-1734

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Duvelisib: 一种2018的新型FDA批准的小分子抑制磷酸肌醇3-激酶

PHARMACEUTICALS

IF4.8

2019-05-0665

OAAI

Recent Advances in Development of Polyphenols as Anticancer Agents

MINI-REVIEWS IN MEDICINAL CHEMISTRY

IF3.3

2018-08-0812

PRE

Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2018-02-15393

PREAI

Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40)

CHEMICAL BIOLOGY & DRUG DESIGN

IF3.3

2017-11-1611

PREAI

Beyond the Selective Inhibition of Histone Deacetylase 6

MINI-REVIEWS IN MEDICINAL CHEMISTRY

IF3.3

2016-08-1120

PRE

Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2016-01-1399

PREAI

Daniel Alencar Rodrigues

个人简介

教育背景

工作经历

荣誉奖项

研究方向